Case reports of etanercept in inflammatory dermatoses - 09/08/11
Correspondence to: J. Mark Jackson, MD, University of Louisville, Division of Dermatology, 444 S First St, Louisville, KY 40202.Fort Lauderdale and Tampa, Florida; San Ramon, California; and Louisville, Kentucky
Abstract |
Skin disfigurations and pruritus can pose severe threats to quality of life, and treatment options for patients with recalcitrant diseases are limited. Tumor necrosis factor ⍺, a proinflammatory cytokine, appears to play a central role in mediating the symptoms of many skin disorders. We report cases in which etanercept (Enbrel; Immunex Corp, Thousand Oaks, Calif), a tumor necrosis factor ⍺ antagonist that is approved for the treatment of moderate to severe psoriasis, was administered to ameliorate the symptoms of acute and chronic dermatologic conditions, including Hailey-Hailey disease, severe psoriasis, dermatomyositis, and subacute cutaneous lupus erythematosus. Treatment with etanercept substantially improved the clinical symptoms and quality of life in these patients, and may offer a therapeutic option for some patients with severe skin disorders.
Le texte complet de cet article est disponible en PDF.Abbreviations used : BSA, HHD, MTX, SCLE, TNF-⍺
Plan
| Supported by Amgen Inc and Wyeth Research. Conflicts of interest: Dr Norman has received no funding for this manuscript and has no conflict of interest. He is a speaker for Novartis and serves on the advisory board for Coloplast. Dr Greenberg has been a consultant and/or member of the speakers bureau for Amgen, Genentech, Biogen/Idec, Connetics, and Centocor. He has received a financial grant for the East Bay Psoriasis Treatment Center. He has no stock ownership in Amgen. Dr Jackson has performed research or consulting, or received honoraria and/or support from the following companies: 3M, Amgen, Biogen, CollaGenex, Connetics, Ferndale, Galderma, Genentech, Medicis, Novartis, and Roche. Dr Jackson owns investment accounts and mutual funds managed by independent money managers; outside of these funds, Dr Jackson has no specific shares in any of the companies. Reprints not available from the authors. |
Vol 54 - N° 3S2
P. S139-S142 - mars 2006 Retour au numéro
Article précédent
- Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
- Gerald G. Krueger, Boni Elewski, Kim Papp, Andrea Wang, Ralph Zitnik, Angelika Jahreis
- What have we learned in dermatology from the biologic therapies?
- Brian J. Nickoloff, Seth R. Stevens
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?